Your CDMO

NerPharMa is a Ddrug development and manufacturing organization
with a strong expertise in oncology

$

SCROLL

NerPharMa

Drug development and manufacturing
organization with a strong
expertise in oncology

Slider

 

$

SCROLL

NerPharMa operates as a CDMO bringing highly potent compounds to the marketplace

 

NerPharma has brought new products and unique innovative technologies to the market over the years, delivering a wide range of GMP services through its agile and flexible facilities.

NerPharMa owns a wide and cutting edge organizational structure able to manage and handle highly active compounds, and to ensure the full development and production of active principles and finished products intended for the world market as well as the research and development of innovative formulation and delivery systems.

In Nerpharma there are two divisions:
NerPharMa DS (drug substance) and NerPharMa DP (drug product)

The two divisions operate in accordance with Current Good Manufacturing Practices (cGMP) and are authorized by the most relevant authorities: Italian Drug Agency (AIFA), U.S. Food and Drug Administration (FDA), ANVISA Brazil, China FDA, PMDA Japan and Russia for the production of both pharmaceutical active ingredients and finished products.

 NerPharma operates worldwide and with more than 30 customers

Product

We have more than 15 products on the market and three unique innovative technologies approved in the last two years.

Expertise

With our deeply and multidiscipilinary expertise we can support our customers in developing and implementing New Chemical Entities and innovative formulations from the scratch.

 About us

We support our customer in every step of the process by providing multiple services including
the production of the active ingredient and its formulation, packaging, clinical supply chain management, and obtaining regulatory approvals in the various countries.

NerPharMa operates since 2010 and our strong specialisation in oncology, our competence and experience make us able to optimise the entire development process till the launch of the product on the market.

From API to drug Product

Nerpharma has two separate divisions:

     NerPharma DP (Drug Product)

can support the development and production of injectable products (solutions, suspensions and lyophilized products) and oral solid products (tablets and capsules) for different therapeutic areas, by handling Proteine Kinase Inibitors, cytotoxic and cytostatic products (not only oncological) and with formulation, packaging and distribution activities.
NerPharMa DP operates in accordance with Current Good Manufacturing Practices (CGMP) and is authorised to manufacture and package Medicinal Products issued by the Italian Regulatory Agency (AIFA).

     NerPharMa DS (Drug Substance)

develops and manufactures exclusively product for oncology (Protein Kinase Inibitor, cytotoxic/cytostatic), from laboratory scale to commercial.
NerPharMa DS operates in accordance with Current Good Manufacturing Practices (CGMP) and is authorised to manufacture of high potent drug substances by the Italian Regulatory Agency (AIFA).

 Services

NerPharMa provides a fully integrated and multidisciplinary support to its customers in order to meet the project milestones on time and with high quality standards.

  Development
and scale-up

We take care of pharmaceutical forms development based on the active ingredient supplied by the customer or manufactured by NerPharma DS, following every phase of the process, from the laboratory to patient kits assembly, the industrialization phase up to the launch of the product on the market.

 Contract Manufacturing

We guide complex compounds securely and efficiently from development through commercial manufacture.

 Regulatory Services

We offer to our partners guidance and consulting in IMPD, IND, DMF, CMC and dossier preparation and filing.

  Clinical Supply

We take care of packaging products used by hospitals for clinical studies. We combine patient kits, consisting of the primary and associated drug.

  Analytical Services

Thanks to our excellent analytical instrumentation, our laboratory is able to develop specific methods to certify and release any type of product on the market.

Latest News & Events

Nerviano Medical Sciences signs research agreement with Università del Piemonte Orientale, Faculty of Pharmaceutical Sciences

Nerviano, 28 June 2022
Nerviano Medical Sciences (NMS Srl) a member of NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancer, is pleased to announce the signing of the agreement with Università del Piemonte Orientale, faculty of Pharmaceutical Sciences in Novara (DSF), as part of the National Operational Programme on Research and Innovation 2014-2020 (Programma Operativo Nazionale (PON) – “RICERCA E INNOVAZIONE” 2014-2020). The Programme is the key instrument with which the Italian government contributes to the improvement of the quality of higher education and the enhancement of research, technological development and innovation.
(Click the title for the complete article)

BrYet Health Inc starts a Manufacturing Development Agreement with NerPharMa for its lead product candidate ML-016 against lung and liver metastases from different type of breast cancer.

Nerviano, 31 May 2022
BrYet Health Inc starts a Manufacturing Development Agreement with NerPharMa for its lead product candidate ML-016 against lung and liver metastases from different type of breast cancer. BrYet is an American biotechnology company based in Houston TX founded for the purpose of developing and bringing to market drugs for prevention and treatment of multiple types of metastatic cancer, based on a disruptive approach developed by Prof. Mauro Ferrari: Transport Oncophysics. BrYet will collaborate with our strategic production partner NerPharMa, a leading CDMO in oncology, to scale-up the drug substance manufacturing process and the finished product to supply material for clinical programs with potential upside to future world-wide commercial sales. The company’s goal is to start ML-016 clinical trials in the second half of 2023.
(Click the title for the complete article)

NMS Group S.p.A. Announces Resignation of Angelo Colombo as CEO of Accelera Srl and NerPharMa Srl; Hugues Dolgos – CEO of NMS Group S.p.A. – Appointed Interim CEO

Nerviano, 5 May 2022
NMS Group SpA today announced that its CEO, Hugues Dolgos, has accepted the resignation of Angelo Colombo as CEO of Accelera Srl and NerPharMa Srl, effective 31 May 2022. Hugues Dolgos will act as interim CEO for both companies. A search for a permanent CEO will begin shortly. (Click the title for the complete article)

Latest Events

Latest News

Careers

 Need more information?

Latest Events

Careers

 Need more information?

 

Welcome and Check out our new motion picture!

WATCH OUR VIDEO